Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA) had its price objective hoisted by Leerink Partners from $27.00 to $29.00 in a research report released on Tuesday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Other research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research report on Wednesday, November 12th. Royal Bank Of Canada boosted their price objective on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating and set a $5.00 price target (down from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. Ten research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.14.

Intellia Therapeutics Stock Down 11.9%

NTLA opened at $13.60 on Tuesday. The company’s 50-day moving average price is $12.09 and its two-hundred day moving average price is $13.10. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -3.55 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.27) earnings per share. As a group, sell-side analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NTLA. Oppenheimer & Co. Inc. boosted its stake in shares of Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares in the last quarter. CWM LLC boosted its position in Intellia Therapeutics by 4.7% during the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after buying an additional 856 shares during the period. Comerica Bank grew its stake in shares of Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after buying an additional 927 shares during the period. Finally, Cyndeo Wealth Partners LLC lifted its stake in shares of Intellia Therapeutics by 9.3% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after acquiring an additional 995 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.